Skip to main content

Lymphoproliferative Disorder clinical trials at UC Davis
2 research studies open to eligible people

  • A Study of Experimetnal Tabelecleucel After Failed Standard Treatment for Solid Organ Transplants With Epstein-Barr Virus

    open to all eligible people

    This is a multicenter, open-label, single-arm phase 3 study to assess the efficacy and safety of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting of solid organ transplant (SOT) after failure of rituximab or rituximab plus chemotherapy.

    Sacramento, California and other locations

  • EVERYCHILD PROTOCOL

    “A REGISTRY, ELIGIBILITY SCREENING, BIOLOGY AND OUTCOME STUDY”

    open to eligible people ages up to 25 years

    This research trial studies the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care.

    Sacramento, California and other locations

Last updated: